Cytec Industries (CYT) Tops Q3 Views; Guides Higher
More News related to CYT
- YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
- Cytec Industries to present at the 2009 Citi Basic Materials Conference
- YM BIOSCIENCES REPORTS CYT997 ORAL VASCULAR DISRUPTING AGENT RESULTS PRESENTED AT AACR-NCI-EORTC MEETING
- After-Hours Movers 11/10: BITS, GSB, OCNF, HOO Higher; TGIC, MCZ, STV, MBLX, EM Lower
- Goldman Sachs Added Cytec Industries (CYT) to their Conviction Sell List
More News related to Earnings
- Notable Analyst Rating Changes 11/24: ABG, PRU, RS, AYI, AMLN, TLAB Upgraded; DELL, CIEN, UNP, ALV Downgraded
- Notable Mergers and Acquisitions of the Day 11/24: WIN/IWA, GMCR/DDRX, PLA
- Morning Movers 11/24: IWA, SEED, FEED, AEZS Higher; WH, ORS, ABIO, GRO, LONG Lower
- After-Hours Movers 11/23: CNO, RMBS, NUAN, ADI Higher; HAYN, DY, DBLE, CISG, IPAR, KWR Lower
- Trading Radar for 11/24: Heinz (HNZ), Dollar Tree (DLTR), Eaton Vance (EV), Hormel Foods (HRL), J. Crew (JCG) Report
Cytec Industries Inc. (NYSE: CYT) reports Q3 EPS of $0.57, 23 cents better than the analyst estimate of $0.34. Revenue for the quarter was $740 million, which compares to the estimate of $710.67 million.
Cytec $0.80-$1.00, versus prior guidance of $0.60-$0.90 and the consensus of $0.80.
Related Categories
EarningsGuidance
Hot List
Stocks Mentioned
-0.74Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
